CN101103954B - Reagent bottle capable of transferring solid-liquid mutually - Google Patents
Reagent bottle capable of transferring solid-liquid mutually Download PDFInfo
- Publication number
- CN101103954B CN101103954B CN 200710101499 CN200710101499A CN101103954B CN 101103954 B CN101103954 B CN 101103954B CN 200710101499 CN200710101499 CN 200710101499 CN 200710101499 A CN200710101499 A CN 200710101499A CN 101103954 B CN101103954 B CN 101103954B
- Authority
- CN
- China
- Prior art keywords
- solid
- membrane
- liposome
- layer
- flos magnoliae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention relates to a reagent glass, in particular to a reagent glass with the transformation of solid and liquid, comprising a tube, an outer casing, a tube cap, a nozzle and a guide tube; wherein the invention also comprises an insulating film and a double-layer cover; the content in the reagent glass is separated into a solid layer and a dissolved layer by the insulating film. The invention which discloses a reagent glass with the transformation of solid and liquid has the advantages that the separation layer between the solid phase and the dissolved solution is a one-off film, like an aluminum film, which can be broken only by rotating the nozzle at one end to achieve the mixture of the two layers of substance, thereby the solid-phase aroma is transformed into the liquid-phase active drug; the solid-phase medicine volatilizes under the action of body heat and the volatilization account is controlled by the mobile cover; the operation is simple and easy.
Description
The application is dividing an application of " a kind of reagent bottle for the treatment of the champignon solid phase preparation of rhinitis and this solid phase preparation being housed " invention.2005 applyings date December 9 days, application number 200510111348.9, denomination of invention: a kind of reagent bottle for the treatment of the champignon solid phase preparation of rhinitis and this solid phase preparation being housed.
Technical field
The present invention relates to a kind of reagent bottle, especially relate to a kind of reagent bottle that solid-liquid is changeed mutually.
Background technology
The Chinese medicine Flos Magnoliae volatile oil is that it is monistic to the treatment right and wrong of allergic rhinitis to one of best medicine of allergic rhinitis treatment.It is a kind of quintessence oil that extracts from the YULAN alabastrum, warm in nature, acrid in the mouth, little hardship, and the pure and fresh fragrance of abnormal smells from the patient has the distinctive fragrance of Chinese medicine, can be used as good scent preparation.The therapeutical effect of Flos Magnoliae mainly contains the following aspects:
(1) antiinflammatory action.It can work to active chronic inflammation by a plurality of links.
(2) anti-allergic effects.Allergic asthma had the obvious suppression effect.
(3) antibiosis and antiviral functions.To golden Portugal bacterium, Diplococcus pneumoniae, bacillus pyocyaneus, escherichia coli etc. all have inhibitory action in various degree.
(4) antihistamine and acetylcholine effect.Histamine and acetylcholine contraction had antagonism;
The capillary permeability that acetylcholine is caused increases inhibited.
(5) anticoagulant, anti-platelet activating factor (PAF) effect.Flos Magnoliae have platelet activation because of
Sub-receptor antagonist activity can suppress the inductive platelet aggregation of PAF;
(6) effect to mucomembranous cilium has the raising effect to frog oral mucosa cilium transporting velocity, and can prolong the persistent period of the stripped oral mucosa fibre swing of the frog.
(7) blood flow increasing: the blood flow that can increase endovascular blood flow of ear and nasal mucosa.
In addition. Flos Magnoliae volatile oil also has the effect of anticancer, analgesia, excited breathing, immunoregulation effect, hypotensive effect, contraction mucosa blood vessel.
In the modern times, people are the uphold nature therapy more and more, and treatment by Chinese herbs is mainly paid attention to is inherence conditioning to human body, and treatment of diseases is reached the purpose for the treatment of both the principal and secondary aspects of a disease, really fundamentally solves the root of the generation of disease, and the treatment of Chinese medicine more and more causes extensive concern.Because Flos Magnoliae has the effect of expelling pathogenic wind and restoring the functions of orifices in face, be commonly used to the treatment headache traditionally, nasal sinusitis, it is obstructed to have a stuffy nose, turbid nasal discharge, toothache etc.
Along with the expansion of Chinese medicine application and application extensively, the present clinical practice of Flos Magnoliae volatile oil:
1. Flos Magnoliae is to the treatment of cacorhinia.The Flos Magnoliae expelling wind and cold, can up women's head-ornaments and kind clearing the nasal passage, treatment acute and chronic rhinitis, sinusitis etc. especially have special curative effect to allergic rhinitis (allergic rhinitis), the commonly encountered diseases that allergic rhinitis formal name used at school allergic rhinitis are a kind of sickness rate height, the morbidity crowd is wide, harm is big.Showing effect suddenly and repeatedly of allergic rhinitis had a strong impact on people's daily routines.With respect to the present Western medicine of treatment of allergic rhinitis clinically; target spot to the allergic rhinitis treatment is more; can pass through antihistamine; antiallergic; antiinflammatory and to a plurality of links such as the protective effects of mastocyte and allergic rhinitis is made a difference; treatment to allergic rhinitis is the synergism of several mechanism, thereby can obtain better therapeutic effect.
2. Flos Magnoliae volatile oil is to the inhibition of recurrent respiratory tract infection, to THE TREATMENT OF BRONCHIAL ASTHMA.Along with the raising of social industrialization degree, the sickness rate of asthma has the trend of rising, and this makes that exploring a kind of effectively also Therapeutic Method easy to use has very important realistic meaning.And the relation between allergic rhinitis and the bronchial asthma is also very close.Use Flos Magnoliae volatile oil asthma is prevented, particularly the prevention of childhood asthma has good effect.
3. the Flos Magnoliae preparation also has certain inhibitory action to influenza virus.Flos Magnoliae volatile oil can effectively be alleviated cold symptoms mucositis symptom, as watery nasal discharge, sneeze, nasal obstruction etc., particularly effectively prevents children's's influenza.
4. the utilization Flos Magnoliae is treated pruritus, autoimmune disease, chronic nephritis etc.
In the prior treatment method, the utilization rate of Chinese medicine is low, it is slow to take effect; The Western medicine instant effect, but toxic and side effects is big.The refinement of Chinese medicine is from animal and plant body, and raw material sources are extensive, to human body seldom or the totally nontoxic side effect.But the extract oral infiltration rate is slow, and utilization ratio of drug is low, and it is slow to take effect, and therefore is not suitable for the acute attack disease treatment, thereby Chinese medicine is very limited in disease treatment.Therefore improve the administering mode of Chinese medicine, adopt the fast administering mode of infiltration rate to become a kind of important way of improving Chinese medicine disease treatment effect.
Chinese medicine treatment rhinitis administering mode: use the sprayer unit medicine carrying, by the spray pattern administration.Also can be by other device administration, for example: People's Republic of China's patent publication No. is 2676914 to have introduced a kind of fragrance bottle, and it comprises the metal bottle mouth of opening bottle, tool through hole, and metal bottle mouth buckle closure is on the opening of bottle; Through hole one end of metal bottle mouth extends at least two trips, and trip is buckled on the inner wall edge of bottle opening.Adopt trip to realize being connected and fixed between metal bottle mouth and the bottle, its fastness is better, and the bottle opening cuts smooth manufacturing procedure and also can be simplified, and the overall appearance of fragrance bottle also can keep its aesthetic property.
People's Republic of China's patent publication No. is 2676914 to disclose a kind of scalable fragrance bottle, it comprises the heater of bottle, bottle oral area and is buckled in the bottle cap of bottleneck, heater with stretch into the bottle an intravital oil suction core link to each other, the oil suction core passes the adjusting device of the cross section size of the scalable oil suction core that is positioned at bottleneck.Fragrance-fumigating bottom can be regulated fragrance-fumigating bottom according to the deep or light difference of the abnormal smells from the patient of the difference of usage space or perfume incense oil.
The existing champignon reagent bottle of having announced all can not satisfy the designing requirement of Flos Magnoliae as treatment preparation and champignon preparation simultaneously, use inconvenient, can not play two kinds of effects simultaneously or be not suitable for carrying.
Summary of the invention
The object of the invention is to overcome the defective of prior art, and a kind of reagent bottle that solid-liquid is changeed mutually is provided.
The objective of the invention is to realize by following technical method:
A kind of reagent bottle that solid-liquid is changeed mutually comprises body, outer housing, body medicated cap, shower nozzle, conduit, wherein also comprises isolating membrane, Double layer lid, and content is divided into solid layer and dissolving layer by isolating membrane in this reagent bottle.
Material is the champignon solid phase preparation of treatment rhinitis in the described reagent bottle solid layer, and material is one or more of deionized water, phosphate buffered solution, normal saline, biological fluid in the dissolving layer.
Described treatment rhinitis champignon solid phase preparation makes by following method:
A, Flos Magnoliae volatile oil, phospholipid, cholesterol, antioxidant, liposome membrane regulator mix, and are dissolved in the dissolution solvent;
B, the mixed solvent constant temperature reduction vaporization that step a is obtained;
C, the lipid membrane that step b is obtained add concussion dissolving in the buffer, regulate pH value, add adjuvant;
D, the Liposomal dispersion that step c is obtained, the ice-water bath supersound process is through filtering with microporous membrane;
E, the liposome turbid liquor that steps d is obtained add the liposome turbid liquor that the stabilizing agent preparation coats Flos Magnoliae volatile oil in filtrate;
F, step e is obtained liposome turbid liquor add antifreezing agent, lyophilization;
Wherein said dissolution solvent is selected from one or more solvents in chloride alkanes, alcohols solvent and the ethers,
Wherein said adjuvant be selected from controlled slow-release preparation, antiseptic one or more.
Flos Magnoliae volatile oil, phospholipid, cholesterol ratio are 15-8:6-1:2-1 in step a, phospholipid is selected from one or more in soybean lecithin, the Ovum Gallus domesticus Flavus lecithin, antioxidant is selected from one or more in collagen protein, vitamin A acetate, the vitamin E, the antioxidant addition accounts for the 0.1-5% of phospholipid weight, the liposome membrane regulator is selected from sodium cholate, sodium deoxycholate, Triton-100, and liposome membrane regulator addition accounts for the 0.001-2.5% of phospholipid weight.The temperature of evaporating in step b is 28-65 ℃.Regulating pH value in step c is 5.5-7.5, the control slow releasing agent is selected from one or more in Stearyl Amine, the diacetyl phosphoric acid, control slow releasing agent addition accounts for the 5-25% of phospholipid weight, antiseptic is selected from one or more in polyoxyethylene sorbitan monoleate, methyl methyl hydroxybenzoate, the phenyl methyl hydroxybenzoate, and the antiseptic addition accounts for the phospholipid weight ratio less than 0.025%.Ultransonic temperature is at 0-10 ℃ in steps d, and supersonic frequency is at 200-1000Hz, ultransonic effective time 0.5-20 minute.Stabilizing agent is selected from one or more in phosphatidyl glycerol, phosphatidic acid, the stearylamine in step e, and the stabilizing agent addition accounts for the 0.9-4.25% of phospholipid weight.Antifreezing agent is selected from one or more of saccharide, glycerol, dimethyl sulfoxide, N-methylated glycinebetaine and pure apoplexy due to endogenous wind in step f, and the antifreezing agent addition accounts for the 0.5-20% of liposome turbid liquor weight.Liposome turbid liquor is under liquid nitrogen lyophilization 0.1-14 hour in step f.
We invent a kind of reagent bottle that solid-liquid is changeed mutually and have health care and treatment double effects.With respect to traditional treatment rhinitis spray, it has structurally increased isolating membrane and Double layer lid.As long as Double layer lid rotation gently in the direction of the clock, the Double layer lid anglec of rotation can be controlled the evaporation rate that is embedded in the volatile oil in the liposome.Isolating membrane plays the effect of isolated water and solid chemicals.Easy to carry at ordinary times, higher temperature (body temperature) just can make the permeability of liposome improve, the rotation Double layer lid slowly discharge volatile oil component with therapeutical effect, have good health-care effect; During the rhinitis that when allergic rhinitis happens suddenly, happens suddenly, only need screw Double layer lid, open the outer housing of the other end, reverse shower nozzle, shower nozzle is drawing conduit and is rotating together, isolating membrane is destroyed, the solid phase liposome is dispersed in the water again, and vibration evenly just becomes treatment nasal cavity spray, medicine is sprayed directly on to nasal cavity, can effectively carries out therapeutical effect rapidly.
The reagent bottle that the present invention can make solid-liquid change mutually belongs to partly disposable, when being used for keeping healthy at ordinary times, changes solid chemicals approximately weekly one time, only need open Double layer lid and just can easily change dressings, and pencil can use repeatedly, and is simple, convenient, healthy, is beneficial to environmental protection again; When being used for the treatment of owing to destroyed isolating membrane, can't reuse, therefore belong to disposable, non-secondary pollution.
The disclosed a kind of reagent bottle that solid-liquid is changeed mutually of the present invention, its advantage shows:
(1) separate layer of solid phase and lysate is disposable thin film, and as the aluminum film etc., a shower nozzle that only needs to rotate an end just can break, and realizes two-layer material mixing, makes the solid phase champignon be converted into the liquid phase quick-acting medicine;
(2) the solid phase medicine volatilizes under the effect of body temperature, with removable cover control drug volatilization amount, uses simple, convenient.
Description of drawings
Fig. 1 shows a kind of reagent bottle structural representation that solid-liquid is changeed mutually.
The specific embodiment
Below in conjunction with embodiment the present invention is further described.
Embodiment
See also shown in Figure 1, a kind of reagent bottle that solid-liquid is changeed mutually comprises body 6, this body one end is provided with body medicated cap 10, the other end is provided with Double layer lid 5, internal layer 51 is to have the semiclosed lid of minute aperture in the Double layer lid, Double layer lid ectomesoderm 52 is screw lids, be carved with spiral lamination in the screw lid, spiral lamination can have up-narrow and down-wide groove.Body medicated cap 10 1 ends are provided with shower nozzle 1, and this shower nozzle adopts the pressing type shower nozzle, and the press head below is connected with spring (not icon).Shower nozzle 1 periphery is provided with outer housing 8.Top shower nozzle 1 is provided with conduit 7.Be provided with isolating membrane 3 in the body 6, isolating membrane 3 is lightweight thin layer diaphragm seals, and the edge has the breach that closely contacts with conduit.This isolating membrane is divided into solid layer 4 and dissolving layer 2 to content in the reagent bottle.
When being used for keeping healthy at ordinary times, but the just easy adjustment use of tightness that only needs to rotate Double layer lid 5, according to actual needs, the volatile quantity of control medicine.
When being used for the treatment of, because being added with the aluminum film is membranous reagent bottle, the thickness of aluminum film is 0.05cm, be connected with conduit 7 on the top shower nozzle 1, need only rotary nozzle 1 gently, drive conduit 2 and cut aluminum film 3, liquid phase is mixed with the liposome of solid phase encapsulated medicine in the solid layer automatically in the dissolving layer, jolting forms even suspension gently, is sprayed on nasal cavity, absorbs by the nasal cavity inner membrance and can play relief of symptoms and therapeutic purposes rapidly.
The treatment rhinitis champignon solid phase preparation that is loaded on reagent bottle can make by the following method:
200mg soybean lecithin, 750mg Flos Magnoliae volatile oil, 100mg cholesterol, 0.2mg sodium cholate, 1mg collagen protein are dissolved in the mixed solvent of 2:1 methanol/chloroform of 20ml.38 ℃ of constant temperature, reduction vaporizations form lipid membrane, add the phosphate buffer concussion dissolving of 20ml, and regulating pH value is 5.5, adds 10mg Stearyl Amine, 0.05mg polyoxyethylene sorbitan monoleate, obtains big multicell Liposomal dispersion.10 ℃ of ultrasonic temperature, the ice-water bath supersound process is 20 minutes under the supersonic frequency 200Hz condition, form the liposome turbid liquor of uniform monolayer through 0.15 μ m filtering with microporous membrane, in filtrate, add the 8.5mg phosphatidyl glycerol and be prepared into the liposome turbid liquor that coats Flos Magnoliae volatile oil.Measure that entrapped drug carrier liposome mean diameter is 56nm in the suspension, envelop rate is 94.8%, and room temperature was preserved 60 days down, and the solution physicochemical properties are stable, and low temperature was preserved uniform and stable no layering of solution and denaturalization phenomenon 150 days down for 4 ℃.Get the liposome turbid liquor adding 20g glycerol that 500g coats Flos Magnoliae volatile oil, fully mix homogeneously is transferred in the freezing bottle of anti-high pressure, constantly feeds liquid nitrogen and remains under the temperature-26 ℃ environment and take out negative pressure, dry 0.4 hour of quick freezing changes the smectic solid into by solution.
The treatment rhinitis champignon solid phase preparation that is loaded on reagent bottle can make with following method:
200mg Ovum Gallus domesticus Flavus lecithin, 330mg Flos Magnoliae volatile oil, 66mg cholesterol, 2.5mg sodium deoxycholate, 10mg vitamin A acetate are dissolved in the mixed solvent of 30ml methanol.28 ℃ of constant temperature, reduction vaporizations form lipid membrane, add the phosphate buffer concussion dissolving of 20ml, and regulating pH value is 7.0, adds 100mg diacetyl phosphoric acid, 0.1mg methyl methyl hydroxybenzoate, obtains big multicell Liposomal dispersion.1 ℃ of ultrasonic temperature, the ice-water bath supersound process is 10 minutes under the supersonic frequency 600Hz condition, form the liposome turbid liquor of uniform monolayer through 0.15 μ m filtering with microporous membrane, in filtrate, add the 4mg phosphatidic acid and be prepared into the liposome turbid liquor that coats Flos Magnoliae volatile oil.Measure that entrapped drug carrier liposome mean diameter is 73nm in the suspension, envelop rate is 93.6%, and room temperature was preserved 60 days down, and the solution physicochemical properties are stable, and low temperature was preserved uniform and stable no layering of solution and denaturalization phenomenon 150 days down for 4 ℃.Get 500g and coat the liposome turbid liquor adding 35g glucose of Flos Magnoliae volatile oil, abundant mix homogeneously, be transferred in the freezing bottle of anti-high pressure, constantly the feeding liquid nitrogen remains under the temperature-26 ℃ environment and takes out negative pressure, and dry 1 hour of quick freezing changes the smectic solid into by solution.
The also available following method of treatment rhinitis champignon solid phase preparation that is loaded on reagent bottle makes:
The 200mg soybean lecithin, the 1600mg Flos Magnoliae volatile oil, the 200mg cholesterol, 5mgTriton-100, the 5mg vitamin E is dissolved in 40ml chloroform mixed solvent, 65 ℃ of reduction vaporizations form lipid membrane, the phosphate buffer concussion dissolving that adds 20ml, regulating pH value is 7.5, add the 20mg Stearyl Amine, 50mg diacetyl phosphoric acid, 0.1mg phenyl methyl hydroxybenzoate, obtain big multicell Liposomal dispersion, 5 ℃ of ultrasonic temperature, the ice-water bath supersound process is 1 minute under the supersonic frequency 1000Hz condition, form the liposome turbid liquor of uniform monolayer through 0.15 μ m filtering with microporous membrane, in filtrate, add the 2mg stearylamine and be prepared into the liposome turbid liquor that coats Flos Magnoliae volatile oil.Measure that entrapped drug carrier liposome mean diameter is 66nm in the suspension, envelop rate is 95.8%, and room temperature was preserved 60 days down, and the solution physicochemical properties are stable, and low temperature was preserved uniform and stable no layering of solution and denaturalization phenomenon 150 days down for 4 ℃.Get liposome turbid liquor adding 60g N-methylated glycinebetaine that 500g coats Flos Magnoliae volatile oil, fully mix homogeneously is transferred in the freezing bottle of anti-high pressure, constantly feeds liquid nitrogen and remains under the temperature-120 ℃ environment and take out negative pressure, lyophilization 6 hours changes the smectic solid into by solution.
The treatment rhinitis champignon solid phase preparation test of pesticide effectiveness that makes by said method is as follows:
Influence to the allergic rhinitis Cavia porcellus
40 of 300～350g Cavia porcelluss are got in Cavia porcellus allergic rhinitis model preparation, and male and female half and half are divided equally 5 groups, and 8 every group, except that staying one group to do the normal control, all the other four groups, with 24 toluene-2,4-diisocyanates (TDL) collunarium sensitization.Be about to 10%TDL olive oil solution 10 μ l, splash into Cavia porcellus bilateral nostril (every side 5 μ l) with sample injector, once a day, 7d after model is judged successfully, keeps the next day of changing into 1 time continuously, finishes until observing medicine; Matched group drips the same model group of method, dosage of olive oil.
Model judges that rhinocnesmus scratching, sneeze, watery nasal discharge to occur serve as to judge index, gives sensitizer TDL the beginning first, as seen rhinocnesmus scratching in various degree, sneeze in the 30min, see watery nasal discharge behind the 3d, with the sensitization time lengthening, symptom gradually increases the weight of, the time of starting shortens, and presents the above symptom of typical case.The curative action effect is scratched number of times with rhinocnesmus, and sneeze number of times, watery nasal discharge degree (flowing to anterior nares is 1 minute, and surpassing anterior nares is 2 minutes, and watery nasal discharge completely is 3 minutes) be as observation index, and be that last is given behind the TDI in the 30min observing time.
After experimental technique and results model are set up, in grouping administration in the 8th day, every day secondary, in the nostril administration of Cavia porcellus bilateral, matched group gives distilled water with sample injector, continuously 7d, 30min after the last administration, give TDL, respectively organize scratching of Cavia porcellus rhinocnesmus and sneeze number of times, watery nasal discharge degree in the observation 30min, the results are shown in Table 1.
The champignon solid phase preparation of table 1 treatment rhinitis is to the effect (x ± s of Cavia porcellus allergic rhinitis symptom; N=8)
| Group | Dosage μ l only | Scratching (inferior) | Sneeze (inferior) | Watery nasal discharge (branch) |
| Normal control | 100 | 0.3±0.4 | 0.5±0.6 | 0 |
| The model contrast | 100 | 5.2±1.2△ | 12.2±3.6△ | 2.6±1.0△ |
| The ketotifen nasal drop | 100 | 1.9±0.6 ** | 4.3±1.8 ** | 1.0±0.7 ** |
| Flos Magnoliae volatile oil | 100 | 3.6±1.4 * | 8.7±2.8 * | 1.5±0.9 * |
| The champignon solid phase preparation of treatment rhinitis | 100 | 2.4±1.2 ** | 5.2±1.4 ** | 0.8±0.8 ** |
Annotate: compare △ P＜0.01 with the normal control group, compare * P＜005, * * P＜001 with model group
Above-mentioned result of experiment shows: the champignon solid phase preparation of treatment rhinitis can effectively resist the symptom of rhinocnesmus that the Cavia porcellus allergic rhinitis produced, sneeze, watery nasal discharge.Therapeutic effect is better than in conventional Flos Magnoliae volatile oil medicine.
Claims (1)
1. the reagent bottle that solid-liquid is changeed mutually comprises body, outer housing, body medicated cap, shower nozzle, conduit, it is characterized in that: also comprise isolating membrane, Double layer lid, content is divided into solid layer and dissolving layer by isolating membrane in this reagent bottle;
Material is the champignon solid phase preparation of treatment rhinitis in the described solid layer, and material is one or more of deionized water, phosphate buffered solution, normal saline, biological fluid in the dissolving layer;
Described treatment rhinitis champignon solid phase preparation makes by following method:
A, Flos Magnoliae volatile oil, phospholipid, cholesterol, antioxidant, the liposome membrane regulator mixes, be dissolved in the dissolution solvent, obtain mixed solvent, Flos Magnoliae volatile oil described in the step a, phospholipid, the cholesterol ratio is 15-8: 6-1: 2-1, described phospholipid is selected from soybean lecithin, in the Ovum Gallus domesticus Flavus lecithin one or more, described antioxidant is selected from collagen protein, vitamin A acetate, in the vitamin E one or more, described antioxidant addition accounts for the 0.1-5% of phospholipid weight, described liposome membrane regulator is selected from sodium cholate, sodium deoxycholate, Triton-100, described liposome membrane regulator addition accounts for the 0.001-2.5% of phospholipid weight;
B, with the mixed solvent constant temperature reduction vaporization that step a obtains, obtain lipid membrane;
C, the lipid membrane that step b is obtained add concussion dissolving in the buffer, regulate pH value, add adjuvant, obtain Liposomal dispersion;
D, the Liposomal dispersion that step c is obtained, the ice-water bath supersound process through filtering with microporous membrane, obtains liposome turbid liquor;
E, the liposome turbid liquor that steps d is obtained add the liposome turbid liquor that the stabilizing agent preparation coats Flos Magnoliae volatile oil in filtrate;
F, step e is obtained liposome turbid liquor add antifreezing agent, lyophilization;
Wherein said dissolution solvent is selected from one or more solvents in chloride alkanes, alcohols solvent and the ethers;
Wherein said adjuvant be selected from controlled slow-release preparation, antiseptic one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710101499 CN101103954B (en) | 2005-12-09 | 2005-12-09 | Reagent bottle capable of transferring solid-liquid mutually |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710101499 CN101103954B (en) | 2005-12-09 | 2005-12-09 | Reagent bottle capable of transferring solid-liquid mutually |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101113489A Division CN100446755C (en) | 2005-12-09 | 2005-12-09 | Incense-fuming solid-state formulation for treating nasitis and reagent bottle equipped with same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101103954A CN101103954A (en) | 2008-01-16 |
| CN101103954B true CN101103954B (en) | 2011-06-29 |
Family
ID=38998167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710101499 Expired - Fee Related CN101103954B (en) | 2005-12-09 | 2005-12-09 | Reagent bottle capable of transferring solid-liquid mutually |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101103954B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88211600U (en) * | 1988-04-06 | 1988-12-28 | 田斌 | Upper-spraying medicine bottle for nose |
| CN2362485Y (en) * | 1999-02-23 | 2000-02-09 | 鞠海洋 | Injection container |
| US6045823A (en) * | 1996-09-19 | 2000-04-04 | Dragoco Gerberding & Co. Ag | Process for producing solid anhydrous composition, and pharmaceutical and cosmetic products comprising same |
| WO2005034861A2 (en) * | 2003-10-02 | 2005-04-21 | The Bio Balance Corporation | A dried biotherapeutic composition, uses, and device and methods for administration thereof |
-
2005
- 2005-12-09 CN CN 200710101499 patent/CN101103954B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88211600U (en) * | 1988-04-06 | 1988-12-28 | 田斌 | Upper-spraying medicine bottle for nose |
| US6045823A (en) * | 1996-09-19 | 2000-04-04 | Dragoco Gerberding & Co. Ag | Process for producing solid anhydrous composition, and pharmaceutical and cosmetic products comprising same |
| CN2362485Y (en) * | 1999-02-23 | 2000-02-09 | 鞠海洋 | Injection container |
| WO2005034861A2 (en) * | 2003-10-02 | 2005-04-21 | The Bio Balance Corporation | A dried biotherapeutic composition, uses, and device and methods for administration thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王娜等.砂仁挥发油纳米脂质体的制备及其稳定性.上海大学学报（自然科学版）第11卷 第5期.2005,第11卷(第5期),541页. |
| 王娜等.砂仁挥发油纳米脂质体的制备及其稳定性.上海大学学报(自然科学版)第11卷 第5期.2005,第11卷(第5期),541页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101103954A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heinrich et al. | Ethnopharmacology of Mexican asteraceae (compositae) | |
| US20170246120A9 (en) | Herbal compositions including cannabidiol to enhance the sexual experience | |
| JP2023116449A (en) | Devices and methods for treatment of body surface disorders | |
| WO2021179567A1 (en) | Chinese mugwort leaf composite essential oil for relieving sore throat and preparation method therefor | |
| KR20230019268A (en) | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| CN103301254B (en) | Antibacterial liquid used for nasopharyal meatus and preparation method thereof | |
| CN100446755C (en) | Incense-fuming solid-state formulation for treating nasitis and reagent bottle equipped with same | |
| CN101011354B (en) | Asarone submicron emulsion and its preparation method | |
| WO2015082965A2 (en) | Novel chitosan nasal wash | |
| DE202009010937U1 (en) | Monoterpenes for the treatment of respiratory diseases, in particular bronchopulmonary diseases | |
| CN101347436B (en) | Uses of methylprednisolone and derivatives thereof in preparing medicament for treating allergic rhinitis | |
| CN101103954B (en) | Reagent bottle capable of transferring solid-liquid mutually | |
| CN101766647A (en) | Purpose of montmorillonite in treating allergic rhinitis and skin allergy | |
| KR20130060092A (en) | Hydrogel patch for alleviating asthma and rhinitis, which is including aroma essential oils and natural extracts, which has the structure of multi-drug-diffusion-control-layer | |
| CN101472570A (en) | Methods of using a thiazole derivative | |
| CN104840521A (en) | Pharmaceutical composition for treating rhinitis | |
| CN104274750B (en) | A kind of Chinese medicine composition for treating acute bronchitis, the infection of the upper respiratory tract | |
| CN100493530C (en) | Method for preparing coated magnolia fargesii volatile oil nano liposome nasal drops | |
| Effat et al. | Pott’s puffy tumour caused by mucormycosis | |
| CN109010427B (en) | Nasal mucosa moisturizing microemulsion and preparation method thereof | |
| WO2009146104A1 (en) | Formulations, devices and methods for treating and preventing mucositis | |
| CN101524388A (en) | Pharmaceutical composition for curing rhinitis and preparation method thereof | |
| CN101264130A (en) | Film coating agent for treating skin ulcer | |
| ES2398576T3 (en) | Acute treatment of social phobia with a steroid androsta-4,16-dien-3-ol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 Termination date: 20121209 |